Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors

PHASE3TerminatedINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

ObesityMicroalbuminuriaDiabetes Mellitus, Type 2Dyslipidemia

Interventions

DRUG

Rimonabant

20 mg once per day + slightly reduced calorie diet

DRUG

Placebo

placebo once per day + slightly reduced calorie diet

Trial Locations (1)

Sanofi-Aventis Administrative Office, Barcelona